LENZ Therapeutics (NASDAQ:LENZ) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research note issued to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $38.00 target price on the stock.

LENZ has been the topic of a number of other research reports. William Blair upgraded LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Piper Sandler reiterated an “overweight” rating and set a $36.00 price target on shares of LENZ Therapeutics in a research report on Thursday, August 15th. Finally, Raymond James assumed coverage on shares of LENZ Therapeutics in a research report on Friday, September 27th. They issued an “outperform” rating and a $37.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $35.40.

LENZ Therapeutics Trading Up 5.0 %

Shares of NASDAQ:LENZ traded up $1.62 during trading on Thursday, hitting $34.15. 104,805 shares of the company were exchanged, compared to its average volume of 136,035. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $37.13. The stock has a 50 day moving average of $24.70 and a 200 day moving average of $21.07.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. As a group, analysts expect that LENZ Therapeutics will post -3.15 EPS for the current year.

Institutional Trading of LENZ Therapeutics

Several hedge funds have recently added to or reduced their stakes in LENZ. American International Group Inc. bought a new stake in LENZ Therapeutics in the first quarter valued at approximately $44,000. SG Americas Securities LLC bought a new stake in LENZ Therapeutics in the 3rd quarter worth $107,000. GSA Capital Partners LLP purchased a new position in shares of LENZ Therapeutics in the third quarter valued at about $246,000. Squarepoint Ops LLC purchased a new stake in LENZ Therapeutics in the 2nd quarter worth approximately $181,000. Finally, Rhumbline Advisers lifted its stake in LENZ Therapeutics by 265.6% in the second quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock worth $291,000 after acquiring an additional 12,214 shares during the period. 54.32% of the stock is owned by institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.